|
|
Post by bosephe on Jun 27, 2019 2:33:55 GMT -5
Inhaled Insulin David Kendall, MD Mannkind Corporation, Thousand Oaks, California 2019 MEETING AGENDA |
|
|
|
Post by boytroy88 on Jun 27, 2019 7:03:10 GMT -5
Inhaled Insulin David Kendall, MD Mannkind Corporation, Thousand Oaks, California 2019 MEETING AGENDANovember 16 @ 11:10AM |
|
|
|
Post by dh4mizzou on Jun 27, 2019 8:04:22 GMT -5
I'd be interested in hearing this one. Could he be starting the push for a new SOC?
Session 3
12:40
Time in Range: A Critical Appraisal
Lutz Heinemann, PhD
Science & Co., Düsseldorf, Germany
|
|
|
|
Post by bioexec25 on Jun 27, 2019 8:30:49 GMT -5
I'd be interested in hearing this one. Could he be starting the push for a new SOC? Session 3 12:40 Time in Range: A Critical Appraisal Lutz Heinemann, PhD Science & Co., Düsseldorf, Germany Session three will be interesting. Knowing Dr. Kendall, he'll use information coming out of prior presentations during his talk in session seven, e.g. Time in range, etc. |
|
|
|
Post by rockstarrick on Jun 27, 2019 8:57:46 GMT -5
I'd be interested in hearing this one. Could he be starting the push for a new SOC? Session 3 12:40 Time in Range: A Critical Appraisal Lutz Heinemann, PhD Science & Co., Düsseldorf, Germany ((((((((((💥BOOM💥)))))))))) |
|
|
|
Post by sayhey24 on Jun 27, 2019 9:27:05 GMT -5
I'd be interested in hearing this one. Could he be starting the push for a new SOC? Session 3 12:40 Time in Range: A Critical Appraisal Lutz Heinemann, PhD Science & Co., Düsseldorf, Germany I sure hope he is already knee deep in trying to get changes made. I think he told us this is the easiest job he has had but many of us knew he would be in the fight of his life. What we are dealing with here is Newton's first law and hopefully Dr. Kendall can help bring the outside force to move the diabetes community. |
|
|
|
Post by Clement on Jun 27, 2019 9:28:16 GMT -5
|
|
|
|
Post by Clement on Jun 27, 2019 9:49:34 GMT -5
"Lutz Heinemann, PhD Science & Co., Dusseldorf, Germany Lutz Heinemann received his degree in Process Engineering in 1976, after which he studied biology at the University of Düsseldorf, until 1982. After three years as Assistant Professor in the Neurophysiology Department at Düsseldorf University, Professor Heinemann transitioned to the field of Internal Medicine. In 1999, Professor Heinemann co-founded Profil Germany where he was CEO until 2009. He is also a member of the German Diabetes Association (DDG), the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA). Prof. Heinemann has been the Managing Editor of the Journal of Diabetes Science and Technology. His scientific research is focused on insulin pharmacology and diabetes technology. Between 2010 and 2015, he acted as coordinator for the EU-funded project AP@home. " www.diabetestechnology.org/dtm/bios/2018/heinemann.html |
|
|
|
Post by mnholdem on Jun 27, 2019 11:52:15 GMT -5
I'd be interested in hearing this one. Could he be starting the push for a new SOC? Session 3 12:40 Time in Range: A Critical Appraisal Lutz Heinemann, PhD Science & Co., Düsseldorf, Germany Session three will be interesting. Knowing Dr. Kendall, he'll use information coming out of prior presentations during his talk in session seven, e.g. Time in range, etc. Kendall only gets 15 minutes, so every add-on will count. |
|
|
|
Post by ktim on Jun 27, 2019 14:41:25 GMT -5
This is one area where I think there might be hope for a lucky break. If larger studies are funded that show economic, long term health or cardio benefits from improved time in range, could MNKD's small short term trials showing better time in range actually be enough to bridge to the those outcomes? Though perhaps it isn't likely that expensive TIR trials would be conducted, since the BP players probably aren't going to fund them. I'm hoping that there continues to be new trial data on TIR.
|
|
|
|
Post by mango on Jun 27, 2019 15:25:46 GMT -5
This is one area where I think there might be hope for a lucky break. If larger studies are funded that show economic, long term health or cardio benefits from improved time in range, could MNKD's small short term trials showing better time in range actually be enough to bridge to the those outcomes? Though perhaps it isn't likely that expensive TIR trials would be conducted, since the BP players probably aren't going to fund them. I'm hoping that there continues to be new trial data on TIR. Of course more and better TIR will improve those. That's just basic science and no need to have expensive and timely clinical trials for something already known. But, The Insulin Cartel would push for that agenda you mention because they do not want Afrezza to succeed. |
|
|
|
Post by ktim on Jun 27, 2019 16:13:07 GMT -5
This is one area where I think there might be hope for a lucky break. If larger studies are funded that show economic, long term health or cardio benefits from improved time in range, could MNKD's small short term trials showing better time in range actually be enough to bridge to the those outcomes? Though perhaps it isn't likely that expensive TIR trials would be conducted, since the BP players probably aren't going to fund them. I'm hoping that there continues to be new trial data on TIR. Of course more and better TIR will improve those. That's just basic science and no need to have expensive and timely clinical trials for something already known. But, The Insulin Cartel would push for that agenda you mention because they do not want Afrezza to succeed. Well, there is either a need for you to take over control of health care spending or for these trials. Because currently A1c is considered the standard to treat to and that is not going to change without trial results. All along you have postulated that doctors should think differently than they do about the practice of medicine and the role of trial based evidence. I think you've been proven wrong about your desire that doctors will act on what you feel is "basic science". BTW... if you read some of the scant literature available regarding TIR vs A1c vs FBG as treatment metrics, the authors themselves usually conclude by saying that more research is necessary. So you seem to be out of step even with the top researchers in the field. No I do not at all think the insulin "cartel" will push to fund trials studying TIR. That is the agenda I would push for, but I have no illusion that Novo, Lily or Sanofi are going to help with that agenda. |
|
